» Articles » PMID: 32442086

Transcriptional Factors and Protein Biomarkers As Target Therapeutics in Traumatic Spinal Cord and Brain Injury

Overview
Date 2020 May 23
PMID 32442086
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Traumatic injury to the spinal cord (SCI) and brain (TBI) are serious health problems and affect many people every year throughout the world. These devastating injuries are affecting not only patients but also their families socially as well as financially. SCI and TBI lead to neurological dysfunction besides continuous inflammation, ischemia, and necrosis followed by progressive neurodegeneration. There are well-established changes in several other processes such as gene expression as well as protein levels that are the important key factors to control the progression of these diseases. We are not yet able to collect enough knowledge on the underlying mechanisms leading to the altered gene expression profiles and protein levels in SCI and TBI. Cell loss is hastened by the induction or imbalance of pro- or anti-inflammatory expression profiles and transcription factors for cell survival after or during trauma. There is a sequence of events of dysregulation of these factors from early to late stages of trauma that opens a therapeutic window for new interventions to prevent/ restrict the progression of these diseases. There has been increasing interest in the modulation of these factors for improving the patient's quality of life by targeting both SCI and TBI. Here, we review some of the recent transcriptional factors and protein biomarkers that have been developed and discovered in the last decade in the context of targeted therapeutics for SCI and TBI patients.

Citing Articles

Transcriptional and Translational Regulation of Differentially Expressed Genes in Yucatan Miniswine Brain Tissues following Traumatic Brain Injury.

Rai V, Mendoza-Mari Y, Radwan M, Brazdzionis J, Connett D, Miulli D J Bioinform Syst Biol. 2024; 7(1):81-91.

PMID: 38818113 PMC: 11138201. DOI: 10.26502/jbsb.5107080.


Interorgan communication in neurogenic heterotopic ossification: the role of brain-derived extracellular vesicles.

Lu W, Yan J, Wang C, Qin W, Han X, Qin Z Bone Res. 2024; 12(1):11.

PMID: 38383487 PMC: 10881583. DOI: 10.1038/s41413-023-00310-8.


Clinical applications of stem cell-derived exosomes.

Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J Signal Transduct Target Ther. 2024; 9(1):17.

PMID: 38212307 PMC: 10784577. DOI: 10.1038/s41392-023-01704-0.


bFGF-like Activity Supported Tissue Regeneration, Modulated Neuroinflammation, and Rebalanced Ca Homeostasis following Spinal Cord Injury.

Ardizzone A, Bova V, Casili G, Filippone A, Lanza M, Repici A Int J Mol Sci. 2023; 24(19).

PMID: 37834102 PMC: 10572408. DOI: 10.3390/ijms241914654.


Uncovering temporospatial sensitive TBI targeting strategies via in vivo phage display.

Martinez B, Mousa G, Fleck K, MacCulloch T, Diehnelt C, Stephanopoulos N Sci Adv. 2022; 8(29):eabo5047.

PMID: 35867794 PMC: 9307250. DOI: 10.1126/sciadv.abo5047.


References
1.
Memet S . NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol. 2006; 72(9):1180-95. DOI: 10.1016/j.bcp.2006.09.003. View

2.
Dalkilic T, Fallah N, Noonan V, Elizei S, Dong K, Belanger L . Predicting Injury Severity and Neurological Recovery after Acute Cervical Spinal Cord Injury: A Comparison of Cerebrospinal Fluid and Magnetic Resonance Imaging Biomarkers. J Neurotrauma. 2017; 35(3):435-445. DOI: 10.1089/neu.2017.5357. View

3.
Farrokhnia N, Ericsson A, Terent A, Lennmyr F . MEK-inhibitor U0126 in hyperglycaemic focal ischaemic brain injury in the rat. Eur J Clin Invest. 2008; 38(9):679-85. DOI: 10.1111/j.1365-2362.2008.01990.x. View

4.
Dai W, Wang X, Teng H, Li C, Wang B, Wang J . Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats. Int Immunopharmacol. 2018; 66:215-223. DOI: 10.1016/j.intimp.2018.11.029. View

5.
Zhou Y, Wang H, Zhou X, Fang J, Zhu L, Ding K . N-acetylcysteine amide provides neuroprotection via Nrf2-ARE pathway in a mouse model of traumatic brain injury. Drug Des Devel Ther. 2018; 12:4117-4127. PMC: 6284532. DOI: 10.2147/DDDT.S179227. View